Source link : https://newshealth.biz/health-news/dermatomyositis-targeted-drug-shows-promise-vs-placebo/
At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments. Medscape Medical News Source link : https://www.medscape.com/viewarticle/dermatomyositis-targeted-drug-shows-promise-vs-placebo-2026a10009iz?src=rss Author : Publish date : 2026-03-29 16:39:00 Copyright for syndicated content belongs to the linked Source.
The post Dermatomyositis: Targeted Drug Shows Promise vs Placebo first appeared on News Health.
—-
Author : News Health
Publish date : 2026-03-29 16:39:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8